Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Holler, Ernst  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Wertheimer T, Dohse M, Afram G, Weber D, Heidenreich M, Holler B, Kattner A-S, Neubauer A, Mielke S, Ljungman P, et al. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. Ann Hematol. 2021.
Grube M, Wolff D, Ahrens N, Herzberg PY, Herr W, Holler E. ABO blood group antigen mismatch has an impact on outcome after allogeneic peripheral blood stem cell transplantation. Clin Transplant. 2016.
Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023;9(1):27.
Gruber I, Koelbl O, Treutwein M, Zeman F, Herr W, Holler E, Edinger M, Wolff D. Analysis of long-term mortality after total body irradiation-based and melphalan-based chemotherapy conditioning for acute myeloid leukemia. Ann Hematol. 2023.
C
Meedt E, Weber D, Bonifacius A, Eiz-Vesper B, Maecker-Kolhoff B, Delecluse S, Delecluse H-J, Lorenz M, Schwarz K, Meedt ST, et al. Chronic Active Epstein-Barr Virus Infection controlled by allogeneic stem cell transplantation and EBV-specific T-cells. Clin Infect Dis. 2023.
D
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Malki MMAl, Ayuk F, Bader P, Baez J, et al. A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
Weber D, Hiergeist A, Weber M, Dettmer K, Wolff D, Hahn J, Herr W, Gessner A, Holler E. Detrimental effect of broad-spectrum antibiotics on intestinal microbiome diversity in patients after allogeneic stem cell transplantation: Lack of commensal sparing antibiotics. Clin Infect Dis. 2018.
Grube M, Brenmoehl J, Rogler G, Hahn J, Herr W, Holler E. Donor NOD2 SNP13 is associated with septic shock after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015.
I
Gruber I, Koelbl O, Herr W, Holler E, Edinger M, Wolff D. Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation. Radiat Oncol. 2022;17(1):195.
Gjærde LKlingen, Peczynski C, Polge E, Kröger N, de Latour RPeffault, Finke J, Holler E, Blaise D, Helbig G, Salmenniemi U, et al. Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2023.
Doering J, Perl M, Weber D, Banas B, Schulz C, Hamer OW, Angstwurm K, Holler E, Herr W, Edinger M, et al. Incidence and outcome of atypical manifestations of chronic Graft-versus-Host disease - results from a retrospective single-center analysis. Transplant Cell Ther. 2023.
Prado-Acosta M, Jeong S, Utrero-Rico A, Goncharov T, Webster JD, Holler E, Morales G, Dellepiane S, Levine JE, Rothenberg ME, et al. Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects. Sci Transl Med. 2023;15(727):eadf8366.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, et al. International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant. 2015.
Scheidler L, Hippe K, Ghimire S, Weber D, Weber M, Meedt E, Hoffmann P, Lehn P, Burkhardt R, Mamilos A, et al. Intestinal IgA positive plasma cells are highly sensitive indicators of alloreaction early after allogeneic transplantation and associate with both, graft-host disease and relapse related mortality. Haematologica. 2023.
M
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socié G, Medinger M, Passweg J, Teshima T, et al. Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant Cell Ther. 2022.
Jarosch S, Köhlen J, Ghimire S, Orberg EThiele, Hammel M, Gaag D, Evert M, Janssen K-P, Hiergeist A, Gessner A, et al. Multimodal immune cell phenotyping in GI biopsies reveals microbiome-related T cell modulations in human GvHD. Cell Rep Med. 2023;4(7):101125.
O
Karl F, Liang C, Boettcher-Loschinski R, Stoll A, Flamann CSheree, Richter S, Lischer C, Völkl S, Jacobs B, Böttcher M, et al. Oxidative DNA Damage in Reconstituting T-cells is Associated with Relapse and Inferior Survival Following Allo-SCT. Blood. 2022.
P
Meedt E, Hiergeist A, Gessner A, Dettmer K, Liebisch G, Ghimire S, Poeck H, Edinger M, Wolff D, Herr W, et al. Prolonged suppression of butyrate producing bacteria is associated with acute gastrointestinal graft-versus-host disease and transplant related mortality after allogeneic stem cell transplantation. Clin Infect Dis. 2021.
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167.
R
Weber D, Hiergeist A, Weber M, Ghimire S, Salzberger B, Wolff D, Poeck H, Gessner A, Edinger M, Herr W, et al. Restrictive versus permissive use of broad-spectrum antibiotics in patients receiving allogeneic SCT and early fever due to cytokine release syndrome: Evidence for beneficial microbiota protection without increase of infectious complications. Clin Infect Dis. 2023.
Blecha C, Angstwurm K, Wolff D, Holler E, Helbig H, Grassinger J, Rennert J, Kleiter I, Huber E, Schmid C, et al. Retinal Involvement in a Patient with Cerebral Manifestation of Chronic Graft-Versus-Host-Disease. Oncol Res Treat. 2015;38(10):532-534.
S
Hart C, Klatt S, Barop J, Mueller G, Schelker R, Holler E, Huber E, Herr W, Grassinger J. Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016.
T
Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.
V
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, A Ayuk F, Aziz M, Baez J, Choe H, DeFilipp Z, et al. A validated risk stratification that incorporates MAGIC biomarkers predicts long term outcomes in pediatric patients with acute GVHD. Transplant Cell Ther. 2024.